609 Phase 1/2a dose selection of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced solid malignancies
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |